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Abstract
Introduction: Screening for colorectal cancer (CRC) is effective in reducing CRC burden. 
Primary care clinics have an important role in increasing screening. We investigated associations 
between clinic-level CRC screening rates of the clinics serving low income, medically 
underserved population, and clinic-level screening interventions, clinic characteristics and 
community contexts.
Methods: Using data (2015–16) from the Centers for Disease Control and Prevention's (CDC) 
Colorectal Cancer Control Program, we linked clinic-level data with county-level contextual data 
from external sources. Analysis variables included clinic-level CRC screening rates, four different 
evidence-based interventions (EBIs) intended to increase screening, clinic characteristics, and 
clinic contexts. In the analysis (2018), we used weighted ordinary least square multiple regression 
analyses to associate EBIs and other covariates with clinic-level screening rates.
Results: Clinics (N = 581) had an average screening rate of 36.3% (weighted. Client reminders 
had the highest association (5.6 percentage points) with screening rates followed by reducing 
structural barriers (4.9 percentage points), provider assessment and feedback (3.2 percentage 
points), and provider reminders (< 1 percentage point). Increases in the number of EBIs was 
associated with steady increases in the screening rate (5.4 percentage points greater for one EBI). 
Screening rates were 16.4 percentage points higher in clinics with 4 EBIs vs. no EBI. Clinic 
characteristics, contexts (e.g. physician density), and context-EBI interactions were also associated 
with clinic screening rates.
Conclusions: These results may help clinics, especially those serving low income, medically 
underserved populations, select individual or combinations of EBIs suitable to their contexts while 
considering costs.
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1. Introduction
Colorectal cancer (CRC) is the third most prevalent cancer among men and women and the 
second leading cause of cancer related deaths (Centers for Disease Control and Prevention 
(CDC), 2018). In 2015, 140,788 men and women were diagnosed with CRC and 52,396 
deaths were attributed to the disease (U.S. Cancer Statistics Data Visualizations Tool, Based 
on November 2017 Submission Data (1999–2015), 2018). Recent estimates in the United 
States (U.S.) indicate that 39% of CRC cases are found at localized stage compared with 
21% at distant stage with 5-year survival rate of 89.9% and 13.9% (Howlader et al., n.d.), 
respectively.
These data highlight the importance of CRC prevention or early detection. Screening is the 
most effective prevention and early detection strategy to reduce CRC burden (Zauber et al., 
2012). Increased use of screening would reduce overall mortality (Lin et al., 2016) and 
economic burden related to the disease (Etzioni et al., 2003). However, 2015 National Health 
Interview Survey data indicated only 62.4% of persons ages 50–75 received screening tests 
consistent with United States Preventive Services Task Force (USPSTF) recommendations 
(White et al., 2017). Screening rates are often associated with factors including patients' age, 
gender, ethnicity, insurance coverage, and routine clinic visits (Ioannou et al., 2003; 
Beydoun and Beydoun, 2008; Holden et al., 2010). For example, CRC screening use among 
average risk men and women aged 65 and older are 14 to 17 percentage points higher, 
respectively, than among those aged 50–64 years (Tessaro et al., 2006; Meissner et al., 
2006). There are important disparities in CRC screening and outcomes attributed to socio-
demographic factors, insurance coverage and geographic locations (Emmons et al., 2009; 
Wong, 2015; Siegel et al., 2015; Burnett-Hartman et al., 2016). Federally Qualified Health 
Centers (FQHCs), which traditionally serve low-income, medically underserved populations, 
have much lower screening rates than the national average. In 2015, FQHCs' average rate 
was 38.4% compared to the national average of 62.5% (White et al., 2017; 2016 National 
Health Center Data, 2016).
Historically, cancer screening in the U.S. has been predominantly opportunistic, i.e. based 
on individual's decision or health care provider recommendation during health encounters 
(Miles et al., 2004). Recently, public health researchers have promoted more organized 
approaches to screening (Plescia et al., 2012), including maximizing the role of primary care 
in prevention and early detection efforts (Rubin et al., 2015). Primary care clinics are 
uniquely positioned to implement interventions shown to be effective in increasing CRC 
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screening rates (Sarfaty et al., 2013). In 2015, the Centers for Disease Control and 
Prevention (CDC) funded the Colorectal Cancer Control Program (CRCCP), which includes 
30 state, tribal, and university grantees, for five years with the aim to increase CRC 
screening rates and reduce disparities among high need populations. The program prioritized 
populations who were low income, medically underserved and who also had low screening 
rates. CRCCP grantees partner with health systems such as FQHCs and clinics serving the 
priority populations to implement up to four priority evidence-based interventions (EBIs) 
recommended in The Community Guide (Force CPST, 2017) and up to four supporting 
activities (SAs) (Table 1).
To evaluate the CRCCP, the CDC collects a baseline record, including clinic-level screening 
rates, at the time of clinic recruitment followed by an annual record thereafter (Satsangi and 
DeGroff, 2016). Analysis of these clinic data completed after one year of program 
implementation found that grantees were working with the intended population - over 70% 
of clinics were FQHCs and 30% of clinics had populations with 20% or greater uninsured 
patients. Additionally, the average baseline CRC screening rate for clinics was 43%, far 
lower than national rates. Previous research suggests individual-level screening decisions are 
related to clinic factors including size, distance to endoscopy centers, clinical support 
arrangements (Weiss et al., 2013; Yano et al., 2007; Pruitt et al., 2014; Wheeler et al., 2014), 
and contextual factors such as physician density, rural/urban status, and other aspects 
contributing to socio-economic deprivation (Anderson et al., 2013; Calo et al., 2015; Davis 
et al., 2017; Doubeni et al., 2012; Shariff-Marco et al., 2013). CRCCP data allows us to 
explore similar relationships at the clinic level, where little research exists. In this paper, we 
investigated associations between clinic-level screening rates among clinics serving low 
income, medically underserved populations and clinic-level EBI use at baseline, controlling 
for the effects of clinic and contextual factors.
2. Methods
2.1. Population and data
All clinics recruited through the CRCCP's second program year with a baseline CRC 
screening rate reported were included in the analysis. Clinic data included clinic 
characteristics (e.g., size, type, preferred CRC test, proportion of uninsured patients), 
implementation status of EBIs/SAs, and CRC screening rate. Information about the clinic 
data, including related collection and reporting processes, have been previously published 
(Satsangi and DeGroff, 2016; DeGroff et al., 2018). Clinic data are self-reported. The 
baseline screening rates represent the 12-month period prior to program participation 
spanning from 2015 to 2016. We used county-level contextual data from external sources: 
Spatial Impact Factor database (2015), United States Department of Agriculture (USDA) – 
Rural Atlas (2013), and United States Cancer Statistics (USCS) (2015). External data were 
linked with CRCCP clinic data using county identifiers. Contextual data provided county 
level socio-demographic and other health-related information for counties where CRCCP 
clinics were located. The clinic data were collected in 2015–2016 and analysis was 
conducted in 2018.
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2.2. Variables
The outcome/dependent variable was the clinic CRC screening rate, defined as the 
percentage of 50–75 year old clinic patients up-to-date with CRC screening according to 
USPSTF guidelines. Explanatory/independent variables included four dichotomous (0, 1) 
variables for the clinic level EBIs, representing whether the respective EBIs were in place or 
not in place. Other explanatory variables included ones for clinic characteristics and clinic 
contexts. Variables for clinic characteristics included number of SAs, clinic size and type, 
percentage of patients uninsured, preferred screening test type by the clinic, and availability 
of free fecal tests such as fecal immunochemical tests (FIT). All clinic characteristics were 
categorical except the number of SAs which was a count variable. Clinic contextual 
variables (county-level) were all continuous. They included average distance to an 
endoscopy suite in miles from Special Impact Factor database; number of primary care 
providers (PCPs) per 100,000 population, poverty rate (percent in 2014), percent of people 
with college education or higher, percent of Hispanic, Black and Asian residents from Rural 
Atlas – USDA database; and CRC incidence rate (per 100,000 population in 2010–2014) 
from uses.
2.3. Statistical analysis
We used bivariate and multiple regression analyses to associate the clinic-level interventions 
with the dependent variable. We used an ordinary least square (OLS) regression model 
where observations (i.e., clinics) were weighted by the clinic's number of screening eligible 
patients. A P-value p < .05 was used to determine the statistical significance of estimated 
regression coefficients. Bonferroni correction was applied a posteriori to avoid the risk of 
making a type-I error because the study involved simultaneous testing of several hypotheses. 
For Bonferroni correction, we used a p-value of 0.05/34 = 0.0015 where 34 was the total 
number of independent variables including constant tested in these regression models.
We used different OLS models to determine associations between clinic level EBIs and 
clinic screening rates. First, we used bivariate models to examine the association between 
each independent variable and the outcome variable. Next, we used the EBIs + SAs Model 
with covariates limited to EBIs and SAs. The Partial Model extended the EBIs + SAs Model 
by adding clinic characteristic variables as covariates. The Full Model extended the Partial 
Model to include all covariates (Partial Model covariates plus contextual variables).
Additionally, we estimated several regression models using screening rate as the dependent 
variable and different sets of independent variables. We used EBI count (0–4, with 0 EBIs as 
the referent) as the independent variable with no covariates (Bivariate EBI Count Model) 
and with all covariates (Full EBI Count Model). Next, we used every combination of the 4 
EBIs without (Partial Multi-Component Model) and with covariates (Full Multi-Component 
Model). The Multi-Component Models used 15 EBI interaction terms – indicators for each 
combination of EBI categories (0 and 1). Given a large number of covariates used in the 
analysis, we conducted a post-hoc power analysis to detect an effect size of 3% with α = 
0.01 on a sample of 581 clinics. The Full Multi-Component Model had the largest number of 
covariates – a total of 34 predictors. Power analysis showed that with the sample size of 581 
clinics (unweighted), we had at least 94.4% chance of detecting a moderation effect size of 
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3%, if the effect truly is present. All statistical analyses were conducted using STATA 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp 
LLC). Power analysis was conducted using G*Power software by Heinrich Heine 
University. CDC determined this study to be public health practice and exempt from human 
subjects review.
3. Results
Analysis included 581 clinics in total. All results presented were weighted unless specified 
as unweighted. A large proportion (69%, unweighted) of clinics were FQHCs, while other 
types comprised 31% (unweighted) or less (Table 2). After weighting, the share of FQHCs 
was only 54%. More than one fifth of the clinics (22%) reported serving a patient population 
with over 20% uninsured. At least one EBI was used in 87% of clinics with provider 
reminders most often in place (66%). Among clinics, 67% had at least one SA in place. The 
average distance to an endoscopy suite in clinic counties was about 14 miles and there were 
an average of 81 primary care providers (PCPs) per 100,000 population. The average 
population with a college degree or higher was 30%. The average CRC incidence rate was 
46 per 100,000 population (2010–2014).
Regression results are presented in Tables 3-4. All four priority EBIs were positively 
associated with clinic screening rates with statistical significance (Table 3). Results were 
generally consistent across all four models. In the Full Model, client reminders had the most 
substantial association with screening rates (5.6 percentage points) followed by reducing 
structural barriers (4.9 percentage points) and provider assessment and feedback (3.2 
percentage points). Provider reminders were also positively associated with clinic screening 
rates, but the association (< 1 percentage point) was the weakest of all EBIs. The strength of 
the association between EBIs and the outcome was sensitive to model specification. The 
magnitude of the regression coefficients on EBIs were larger in bivariate models compared 
to all other models suggesting their correlations with the added covariates. SAs, although 
statistically significant, were weakly associated with the outcome.
The associations between clinic characteristics and the outcome were mixed. Compared to 
the clinics with less than a 5% uninsured patient population, clinics with 5–20% and above 
20% uninsured patients had lower screening rates (−3.8 and −5.5 percentage points, 
respectively). Both medium and large size clinics were associated with higher clinic 
screening rates compared with small size clinics. Likewise, when compared to FQHCs, all 
other clinic types were associated with higher screening rates. The association ranged from 
9.4 percentage points for health department clinics to 16.2 percentage points for health 
system/hospital owned clinics. Clinics using FIT as the primary CRC screening test and 
providing free fecal test kits were both associated with lower screening rates than clinics 
primarily referring for colonoscopy (−2.5 and −6.3 percentage points respectively).
The average distance to endoscopy suites and the number of PCPs per 100,000 population 
were negatively associated with clinic screening rates. The percent of county population 
with a college degree and higher had the largest positive association with clinic screening 
rates (0.7 percentage points) followed by percent of the non-Hispanic Asian population (0.4) 
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and CRC incidence rate (0.3). Poverty rates (0.2) and percent of the Hispanic population 
percentage (0.1) in counties were also associated positively while the percentage of non-
Hispanic Black populations was associated negatively with clinic screening rates.
3.1. Combinations of EBIs
Overall, when controlling for clinic and contextual factors, higher numbers of EBIs were 
associated with a steady increase in clinic screening rates from 5.4 percentage points for any 
one EBI to 15.1 percentage points for all 4 EBIs (Table 4, Full EBI Count Model). However, 
compared to no EBIs, different combinations of two or more EBIs did not have similarly 
steady associations with the outcome. Some inconsistencies were likely due to the small 
number of clinics in the group. However, a consistent pattern emerged when clinics had any 
of three or all four EBIs in place. Clinics with three or four EBIs in place had 9.1 to 16.4 
percentage points higher screening rates compared to those with none in place (Table 4, Full 
Multi-Component Model). Almost all estimated statistically significant coefficients in Table 
3 and Table 4 remained significant at 5% level after Bonferroni correction. Boldface 
indicates statistical significance at 5% level even after Bonferroni correction.
4. Discussion
In this exploratory work, we used a unique dataset from CDC's CRCCP to measure 
associations between EBIs recommended in The Community Guide and baseline clinic-level 
CRC screening rates. The study was not designed to measure causal impact, therefore, the 
estimated associations do not necessarily indicate causal links between covariates and CRC 
screening rates.
These results contribute to the literature by showing that the four priority EBIs used in the 
CRCCP are positively associated with screening use in low-resourced, community-based 
settings including FQHCs and local health department clinics serving low income, medically 
underserved populations. Given that all EBIs and almost all EBI combinations were 
associated with higher mean clinic screening rates, clinics may be able to choose to 
implement EBIs most suitable and least costly to them. Findings indicate that all individual 
EBIs, all numbers of EBIs, and all combinations of EBIs, except one, were associated with 
increased screening use. Thus, clinics may be able to select EBIs or combinations of EBIs 
that they believe best address their local needs. However, findings also indicate that some 
EBIs and combinations of EBIs may be associated with greater screening use than others. 
For example, larger numbers of EBIs were associated with higher screening use than a single 
EBI.
Our results are consistent with past studies, and, therefore, further strengthen the body of 
evidence tying these interventions to increased screening use. A systematic review (Holden 
et al., 2010) of past studies found that the influence of client reminders on CRC screening 
rates ranged from 5 to 15 percentage points and no influence of provider reminder, 
consistent with our estimates. However, the same study found that eliminating structural 
barriers increased CRC screening rates by 15.0 to 42.0 percentage points, much higher than 
our finding of association between reducing structural barriers and clinic level screening 
rates. A meta-analysis of evidence on CRC screening interventions examined the effect of 
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provider assessment and feedback, client reminders, and provider reminders (Stone et al., 
2002). Among the three EBIs, client reminders had the greatest effect, followed by provider 
reminders and provider assessment and feedback. Our results found client reminders and 
reducing structural barriers to have greater associations with screening rates, followed by 
provider assessment and feedback and provider reminders. Our finding that supporting 
activities were weakly, although positively, associated with screening rates are also 
compatible with results from a past study (Holden et al., 2010). However, we should note 
that, unlike the past systematic reviews/meta analyses cited above, our unit of analysis was 
the clinic, not patients. This implies that using clinics as the unit of analysis also allows us to 
reach similar conclusions about the relationships between interventions and outcomes.
Our finding of the significant and negative association between the percent uninsured in a 
clinic and screening rate was expected, corroborating findings from previous studies 
(Beydoun and Beydoun, 2008; Holden et al., 2010). That non-FQHC clinics had higher 
screening rates than FQHCs may highlight the fact that the latter serve patients who are 
more disadvantaged with lower screening rates than other populations included in this study. 
Similarly, our finding that clinics with larger patient populations had higher screening rates 
suggests availability of resources and clinic capacity may underlie their performance. 
Programmatically, because EBIs can be resource-intensive to implement irrespective of the 
clinic size, our results support targeting larger clinics, when feasible and appropriate, where 
greater impact can be achieved. Our finding that clinics primarily using FIT tests or 
providing free fecal kits were associated with lower screening rates might represent a 
relationship between clinics preferring FIT tests and clinics with lower screening rates (such 
as FQHCs). Additionally, assuring annual FIT testing may be more difficult in contrast to 
colonoscopy which is required only once each 10 years.
Importantly, findings indicate stronger associations with higher screening rates when 
multiple EBIs were implemented. Additionally, the association between the number of EBIs 
and clinic screening rates increased steadily as the number of EBIs increased. Unlike the 
combinations of two EBIs, any combination of three or all four EBIs had greater and more 
consistent associations with higher screening rates. We also observed that having provider 
reminders in the EBI combination was associated with a smaller increase in screening rates 
than not having it. This reconfirms the weaker association of provider reminders we 
observed as an independent EBI in the base model. Together, these results for two or more 
EBI combinations are consistent with evidence supporting multi-component interventions 
reported in the past by the Community Preventive Services Task Force (Weiss et al., 2013) 
and other studies (Power et al, 2009; Community-Preventive-Services-Task-Force, 2016). 
Further, the effectiveness of these EBIs can substantially vary by context. Future work in this 
area can evaluate the association between EBIs and screening rate in different contexts.
4.1. Limitations
Several limitations are noted. First, the clinic data are self-reported by CRCCP awardees and 
we lacked information on the quality or intensity of EBI implementation. Consequently, the 
effectiveness of EBIs likely varied across clinics. Moreover, grantees follow 
recommendations detailed in The Community Guide about these strategies which could be 
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different than the way they have been implemented in studies that established their 
effectiveness. Second, the data do not capture all variables likely to influence and explain 
variation in clinic-level screening rates. This implies our results may suffer from omitted 
variable bias, similar to most regression models. Some important omitted variables in this 
study include those that capture characteristics of individual patients (e.g. age, education, 
insurance coverage and other barriers) and the ability of clinics to implement EBIs including 
EBI quality and intensity. Also, the use of county-level information cannot sufficiently 
capture the variations in contexts with potential ecological biases in results. With county-
level variables, we can only interpret those effects as change in outcomes associated with 
change in clinic contexts (such as socio-demographic characteristics of the population 
served) represented by those variables. Making inferences on clinic-level relationships using 
aggregated county-level data could potentially suffer from ecological fallacy (i.e. individual 
level relationships can be eclipsed due to data aggregation). Further, as associations are not 
causal, other factors may have confounded relationships with EBIs and clinic screening 
rates. For instance, a clinic's ability to implement multiple EBIs might also be influenced by 
its culture, priorities, and supporting infrastructure. Existence of these factors might affect 
screening use through avenues other than the implementation of EBIs. Finally, this study 
was conducted primarily among clinics serving low income, medically underserved 
populations in community clinics such as FQHCs. The generalizability of these results, 
therefore, is limited.
5. Conclusions
Results from our analysis provide new insights on how clinic-level interventions including 
EBIs and SAs, clinic characteristics, and contextual factors are associated with clinic-level 
CRC screening rates. Such insights, combined with other practical considerations, can 
inform the design and implementation of clinic-focused, organized approaches to increase 
CRC screening rates.
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